Oxford Immunotec Global (OXFD) Lifted to “Buy” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a hold rating to a buy rating in a research note issued to investors on Thursday. They currently have $16.00 price target on the stock.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

Several other research analysts also recently commented on OXFD. ValuEngine raised shares of Oxford Immunotec Global from a hold rating to a buy rating in a research note on Wednesday, September 12th. BidaskClub raised shares of Oxford Immunotec Global from a sell rating to a hold rating in a research note on Thursday, October 18th. Finally, Piper Jaffray Companies reaffirmed an overweight rating on shares of Oxford Immunotec Global in a research note on Sunday, November 11th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Oxford Immunotec Global currently has a consensus rating of Buy and a consensus price target of $16.67.

Shares of NASDAQ OXFD traded up $0.02 during mid-day trading on Thursday, hitting $14.90. The stock had a trading volume of 106,500 shares, compared to its average volume of 104,300. Oxford Immunotec Global has a 1 year low of $10.00 and a 1 year high of $19.19. The company has a market cap of $387.25 million, a price-to-earnings ratio of -10.96 and a beta of 0.11.

Oxford Immunotec Global (NASDAQ:OXFD) last issued its earnings results on Friday, November 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.14). Oxford Immunotec Global had a negative return on equity of 41.15% and a negative net margin of 12.51%. The firm had revenue of $16.10 million during the quarter, compared to analysts’ expectations of $33.60 million. During the same period in the previous year, the firm earned ($0.70) earnings per share. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. As a group, equities analysts predict that Oxford Immunotec Global will post -1.09 EPS for the current year.

In other Oxford Immunotec Global news, CEO Peter Wrighton-Smith sold 10,000 shares of the business’s stock in a transaction on Thursday, January 10th. The shares were sold at an average price of $14.91, for a total transaction of $149,100.00. Following the transaction, the chief executive officer now directly owns 423,469 shares of the company’s stock, valued at approximately $6,313,922.79. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $15.50, for a total transaction of $46,500.00. Following the transaction, the director now directly owns 9,000 shares in the company, valued at $139,500. The disclosure for this sale can be found here. 6.61% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of OXFD. Engineers Gate Manager LP purchased a new stake in shares of Oxford Immunotec Global in the 3rd quarter worth about $188,000. Trexquant Investment LP purchased a new stake in shares of Oxford Immunotec Global in the 3rd quarter worth about $279,000. Renaissance Technologies LLC grew its position in shares of Oxford Immunotec Global by 84.7% in the 2nd quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock worth $271,000 after buying an additional 9,658 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Oxford Immunotec Global in the 3rd quarter worth about $445,000. Finally, Hound Partners LLC purchased a new stake in shares of Oxford Immunotec Global in the 3rd quarter worth about $524,000. 90.94% of the stock is currently owned by institutional investors and hedge funds.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Featured Story: What impact do institutional investors have on markets?

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Comparing Adaptimmune Therapeutics  and Allogene Therapeutics
Comparing Adaptimmune Therapeutics and Allogene Therapeutics
Daniel Wright Buys 3,249 Shares of Manchester & London Investment Trust plc  Stock
Daniel Wright Buys 3,249 Shares of Manchester & London Investment Trust plc Stock
AbbVie  Scheduled to Post Earnings on Friday
AbbVie Scheduled to Post Earnings on Friday
Comparing Sono-Tek  and Maxwell Technologies
Comparing Sono-Tek and Maxwell Technologies
Lithium Americas  vs. Cleveland-Cliffs  Financial Contrast
Lithium Americas vs. Cleveland-Cliffs Financial Contrast
BidaskClub Downgrades P.A.M. Transportation Services  to Sell
BidaskClub Downgrades P.A.M. Transportation Services to Sell


Leave a Reply

 
© 2006-2019 Zolmax.